Triad Therapeutics
This article was originally published in The Gray Sheet
Executive Summary
Nuclear magnetic resonance technology firm raises $30 mil. in Series B private placement led by Credit Suisse First Boston Private Equity. Funds will go towards developing the San Diego firm's proprietary chemistry technology platform. The device produces high-affinity lead compounds for facilitating small-molecule drug discovery. Investors participating in the round included Skyline Ventures, H&Q Life Science and J&J Development Corp